Office of Corporate Alliances, University of Rochester Medical Center

Connecting corporate and academic researchers to advance science and human health

  

 

Commercial Achievements

Learn about the highlights of our achievementsURMC research has resulted in numerous commercial achievements. Through technology licensing and business development, URMC researchers translate discoveries into biomedical advancement. Please visit our Highlights of Commercial Achievement page to discover our history of commercial successes.

Licensing

The immense creativity of URMC scientists is evidenced by the nearly 500 invention disclosures evaluated by the URMC’s Office of Technology Transfer (OTT) since its inception in 2001.

Ever mindful of the commercial potential of biomedical advances, OTT manages the intellectual property of URMC and its inventors. OTT has secured patent rights to 64 inventions since 2000, with 51 provisional patent applications filed in 2005 alone. Also, the number of technology licensing agreements based on URMC inventions constructed and administered by OTT has grown from 24 to 67 in an eight-year period.

URMC has enjoyed significant success translating discoveries to commercially viable medical advances. As a result, royalties paid to URMC and its inventors since 2001 total nearly $120 million. Currently, OTT has more than 300 technologies available for licensing.

For more information, visit the URMC Office of Technology Transfer.

Start-Up Companies

The desire to deliver medical advancements to the public fuels our inventor-entrepreneurs’ drive to form start-up companies based on URMC discoveries. Business development efforts have resulted in the following companies with origins at the URMC:

  • CAS LLC will provide evaluation services in clinical trials of Alzheimer’s disease therapies.
  • iCardiac Technologies develops and markets novel advanced ECG-based biomarkers.
  • Koning Corporation employs advanced 3-D imaging technology to visualize tiny breast tumors.
  • LAGeT Inc. employs a novel system for modulating gene therapy in musculoskeletal indications.
  • OyaGen Inc. exploits an innate mechanism of HIV resistance to develop a new class of HIV therapeutics.
  • Pathologics Inc. is developing a platform-based, biological diagnostic system.
  • Physiologic Communications, LLC (PhysioComm) provides advanced diagnostic, monitoring, and therapeutic solutions, including implantable biosensors.
  • RTek Medical Systems LLC developed an imaging system to aid in the planning of prostate cancer therapy.
  • Socratech LLC is developing new diagnostic and therapeutic approached to address Alzheimer’s disease.
  • Vaccinex Inc. engages in therapeutic antibody discovery.
  • VirtualScopics LLC’s technology turns CT scans into 3-D color images.